Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications

George Pettit, J. K. Srirangam, J. Barkoczy, M. D. Williams, K. P M Durkin, M. R. Boyd, R. Bai, E. Hamel, J. M. Schmidt, Jean Chapuis

Research output: Contribution to journalArticle

83 Scopus citations


New structural modifications of the marine shell-less mollusk peptide constituent dolastatin 10 (1) have been synthesized, and evaluated against a variety of cancer cell lines and for their ability to inhibit tubulin polymerization. A number of useful structure-activity relationships were uncovered. The most important observation was that the dolaphenine unit of dolastatin 10 could be satisfactorily replaced with a phenethylamine. Peptide 11C, designated auristatin PE, was found to exhibit inhibition of cancer cell growth and tubulin assembly comparable to that of dolastatin 10.

Original languageEnglish (US)
Pages (from-to)529-544
Number of pages16
JournalAnti-Cancer Drug Design
Issue number7
StatePublished - Jan 1 1995


  • Antineoplastic agents
  • Dolastatin 10
  • Structural modifications

ASJC Scopus subject areas

  • Biochemistry
  • Oncology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications'. Together they form a unique fingerprint.

  • Cite this

    Pettit, G., Srirangam, J. K., Barkoczy, J., Williams, M. D., Durkin, K. P. M., Boyd, M. R., Bai, R., Hamel, E., Schmidt, J. M., & Chapuis, J. (1995). Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anti-Cancer Drug Design, 10(7), 529-544.